To the Editor In their recently published Research Letter,1 Carr and Welch are right to raise concerns about the influence of industry funding on clinical research. However, their article implies that all such relationships are inherently problematic, despite the lack of details about the services provided. It is also not apparent whether any cancer center directors were contacted by the authors regarding the circumstances of their relationships to the pharmaceutical industry.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Jensen RA, Knudsen KE, Platanias LC. Disclose and Manage Conflicts of Interest at Cancer Centers. JAMA Intern Med. 2020;180(1):161. doi:10.1001/jamainternmed.2019.5542
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: